富士製薬工業(株)の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|
| 東証PRM | 医薬品 | 4554/E00975 | - |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|
| 2022/05/06 | 日証協 | 59,375株 | -9.59% | 1,500株 | -31.19% | 331,491株 | -0.81% | 1,800株 | -94.77% |
| 2022/04/28 | 日証協 | 65,675株 | -16.23% | 2,180株 | -86.87% | 334,191株 | -1.25% | 34,401株 | -50.59% |
| 2022/04/22 | 日証協 | 78,402株 | +21.74% | 16,600株 | +3.11% | 338,415株 | +1.96% | 69,622株 | -7.42% |
| 2022/04/15 | 日証協 | 64,402株 | +4.38% | 16,100株 | -55.03% | 331,895株 | +1.47% | 75,200株 | +31.01% |
| 2022/04/08 | 日証協 | 61,702株 | -2.53% | 35,800株 | +98.89% | 327,095株 | -3.05% | 57,400株 | -79.95% |
| 2022/04/01 | 日証協 | 63,302株 | +1.77% | 18,000株 | -34.55% | 337,384株 | +6.1% | 286,269株 | +621.08% |
| 2022/03/25 | 日証協 | 62,202株 | -21.27% | 27,500株 | +22.22% | 317,984株 | -4.02% | 39,700株 | -23.25% |
| 2022/03/18 | 日証協 | 79,002株 | -1.62% | 22,500株 | +52.03% | 331,317株 | +4.88% | 51,728株 | -11.61% |
| 2022/03/11 | 日証協 | 80,302株 | +5.94% | 14,800株 | -5.73% | 315,904株 | +18.14% | 58,520株 | +34.49% |
| 2022/03/04 | 日証協 | 75,802株 | -23.74% | 15,700株 | -18.65% | 267,393株 | +0.3% | 43,512株 | +100.52% |
| 2022/02/25 | 日証協 | 99,402株 | +17.91% | 19,300株 | +156% | 266,584株 | +1.99% | 21,700株 | -23.79% |
| 2022/02/18 | 日証協 | 84,302株 | -9.89% | 7,539株 | -57.81% | 261,384株 | -0.47% | 28,473株 | -8.72% |
| 2022/02/10 | 日証協 | 93,558株 | +19.79% | 17,868株 | +19.37% | 262,615株 | +6.25% | 31,194株 | -16.15% |
| 2022/02/04 | 日証協 | 78,102株 | -25.26% | 14,968株 | -18.26% | 247,159株 | -8.51% | 37,200株 | +14.07% |
| 2022/01/28 | 日証協 | 104,494株 | -2.88% | 18,312株 | -43.74% | 270,151株 | -5.19% | 32,612株 | -41.76% |
| 2022/01/21 | 日証協 | 107,594株 | +25.1% | 32,550株 | +104.72% | 284,941株 | +10.12% | 55,994株 | +297.12% |
| 2022/01/14 | 日証協 | 86,006株 | -2.71% | 15,900株 | +504.33% | 258,749株 | +2.5% | 14,100株 | -8.49% |
| 2022/01/07 | 日証協 | 88,406株 | -5.93% | 2,631株 | -38.81% | 252,448株 | -0.08% | 15,408株 | +37.83% |
| 2021/12/30 | 日証協 | 93,975株 | 0% | 4,300株 | 0% | 252,651株 | 0% | 11,179株 | 0% |
※株式分割は考慮していませんのでご注意ください。
Page Top